Nordicus Partners Corporation filings document material-event disclosures for a public life sciences holding and business-acceleration company. The company’s Form 8-K reports cover capital-structure actions, including private placements and unregistered sales of restricted common stock under Securities Act exemptions.
The filing record also documents governance actions, including the establishment of board committees and adoption of Audit Committee, Compensation Committee, and Nominating Committee charters. These disclosures describe formal board structure, committee responsibilities, equity issuance terms, investor qualification representations, transfer restrictions, and related regulatory exemptions.
Nordicus Partners Corp issued a $147,000 principal promissory note to ABCHill Holding ApS on October 15, 2026. The note is payable on demand and bears interest at the lesser of 6.0% per annum and the maximum rate permitted by applicable law, calculated using a 365-day year and actual days elapsed.
ABCHill Holding ApS is wholly owned and controlled by Christian Hill-Madsen, a director of Nordicus subsidiaries Orocidin A/S and Bio-Convert A/S, CEO of NP Bioinnovation A/S, and COO of NoviThera ApS. Nordicus may prepay the note in whole or in part at any time without premium or penalty. Payments are applied first to accrued interest, then principal. Following a default, including nonpayment or certain insolvency events, the lender may declare all amounts immediately due and payable and pursue customary remedies, including collection costs and attorneys’ fees. The note was issued in reliance on the Securities Act Section 4(a)(2) exemption and has not been registered.
Nordicus Partners Corp (NORD) issued a $75,000 promissory note to AC Nordic ApS, which is wholly owned and controlled by Torben Jensen, a member of the Company’s Board of Directors. The note is payable on demand and bears interest at the lesser of 6.0% per annum and the maximum rate permitted by applicable law, calculated on a 365-day year and actual days elapsed.
The Company intends to use the proceeds for working capital and general corporate purposes. Disinterested directors approved the related-party transaction after disclosure of Mr. Jensen’s interest; he abstained. The Company may prepay the note, in whole or in part, at any time without premium or penalty.
Nordicus Partners Corp (NORD) reported no revenue for the three months ended June 30, 2026, and a net loss attributable to Nordicus of $2,276,302, compared with $1,206,886 a year earlier. Cash was $5,784 at quarter-end; operating activities used $159,844, versus $425,698 a year earlier. The company reported a $53,245,739 accumulated deficit and stated that current funds would not meet its needs for more than twelve months from issuance, creating substantial doubt about its ability to continue as a going concern.
Orocidin reported efficacy for QR-01 in dog and rat studies; its Phase IIa trial is anticipated in the first half of 2027. Bio-Convert anticipates Phase IIa trials in Europe beginning in the first half of 2027. On September 10, 2026, Nordicus issued a convertible note with $600,000 principal for $500,000 cash, bearing 5.0% annual interest and maturing June 10, 2027; the company also agreed to issue 250,000 commitment shares. Conversion is available to the lender only upon and during an event of default, and only from June 10, 2027, at 90% of the volume-weighted average price over the 10 trading days before a conversion request.
Nordicus Partners Corp (NORD) entered into a financing with Keystone Capital Partners LLC via a $600,000 Convertible Grid Promissory Note on September 10, 2026, for which it received $500,000 in cash. The Note bears 5.0% annual interest and matures on June 10, 2027, with principal due at maturity.
As funding consideration, Nordicus issued 250,000 commitment shares of common stock. Upon and only after an Event of Default and from and after June 10, 2027, the lender may convert principal and accrued interest into common stock at 90% of the 10‑day VWAP, with an additional 5% discount and a $750 fee per conversion if DTC trading becomes chilled and is not cured within ten business days. The Note may be prepaid at 120% of outstanding principal.
Nordicus agreed to file, by November 1, 2026, a resale registration statement for shares issuable upon conversion and granted the lender piggyback registration rights. The Note, commitment shares and any conversion shares were issued as unregistered securities in a private offering relying on Section 4(a)(2) and/or Rule 506(b) of Regulation D, with no underwriters or commissions.
Nordicus Partners Corporation (NORD) reported that its Board of Directors appointed Elizabeth Addonizio as a director effective September 1, 2026, filling the vacancy created by the recent resignation of Andrew Ritter. The company entered into a Director’s Agreement with her providing a $10,000 annual cash retainer and options to purchase 25,000 shares of common stock at $4.09 per share, fully vested on the grant date under the 2024 Stock Incentive Plan. Nordicus describes her as an independent director with 25 years of finance experience in investment banking, private equity, and venture investing, as well as extensive U.S. Navy Reserve leadership experience. A related indemnification agreement and a press release announcing the appointment are included as exhibits.
Nordicus Partners Corporation notified that its Quarterly Report on Form 10-Q for the quarter ended June 30, 2026 will be filed late. The company states it could not complete accounting records and schedules in time for its independent auditor to review the financial statements without unreasonable effort and expense. It expects to file the Form 10-Q, including unaudited financial statements, within the permitted 5-day extension and anticipates reporting a net loss of approximately $2,300,00 on revenues of $0 for the quarter.
Nordicus Partners Corporation is a U.S.-listed biotech focused on acquiring and developing Nordic-origin drugs for diseases with unmet medical needs, initially in oral disorders and psoriasis. For the year ended March 31, 2026 it generated no revenue (versus $5,000 a year earlier) and reported a net loss attributable to the company of $4.0 million, or $0.22 per share, driven by higher R&D and corporate expenses.
Operating expenses were $4.37 million, including $1.61 million of research and development across three preclinical programs: Orocidin’s QR-01 for periodontitis, Bio-Convert’s QR-02 for oral leukoplakia, and NoviThera’s QR-04 for psoriasis. QR-01 showed efficacy in dog and rat models and QR-02 received a toxicity waiver and is moving toward GMP production, with both programs anticipating Phase IIa trials in the first half of 2027. NoviThera achieved biological proof of concept in a mouse study.
Liquidity is constrained: cash was only $20,878 at March 31, 2026 after using $4.32 million in operating cash flows, largely offset by $4.34 million raised from equity issuances. The independent auditor cited nominal revenue, recurring losses and an accumulated deficit as raising substantial doubt about Nordicus’s ability to continue as a going concern. Management is seeking additional capital and has applied to uplist its shares to the Nasdaq Capital Market.
Nordicus Partners Corporation reported a governance change involving its board of directors. On July 7, 2026, Andrew J. Ritter resigned from the Board of Directors, effective immediately, and also stepped down from the Audit Committee, Compensation Committee, and Nominating and Corporate Governance Committee.
The company states that Mr. Ritter resigned to pursue other time-consuming business opportunities and that his resignation was not the result of any disagreement with Nordicus Partners on matters relating to its operations, policies, or practices. No financial results or major transactions are described in this report.
Nordicus Partners Corporation notified the SEC it could not file its Annual Report on Form 10-K for the fiscal year ended March 31, 2026 on time and expects to file within the 15-calendar-day extension.
The company anticipates reporting a net loss of approximately $346,731 on $0 revenues for the year. The delay reflects the need to complete accounting records and allow the independent auditor to finish the audit.
Nordicus Partners Corporation entered into a material definitive agreement related to a private stock offering, issuing 201,500 restricted shares of common stock at $2.75 per share to five private investors in March and April 2026. On June 23, 2026, the company determined to close this private offering on those terms.
The shares were issued without SEC registration, relying on exemptions under Section 4(a)(2) of the Securities Act, Rule 506(b) and (c) of Regulation D, and Regulation S for non-U.S. persons. No underwriters or agents were involved, no underwriting discounts or commissions were paid, and the securities carry transfer restrictions and a legend noting they are not registered and cannot be resold without registration or a valid exemption.